Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Hypoxia D000860 23 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Tumor Virus Infections D014412 8 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Pain D010146 64 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Pulmonary Fibrosis D011658 24 associated lipids
Wounds and Injuries D014947 20 associated lipids
Pleurisy D010998 20 associated lipids
Burns D002056 34 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Inflammation D007249 119 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Infertility, Male D007248 11 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Brain Injuries D001930 4 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Gastritis D005756 27 associated lipids
Pulmonary Edema D011654 23 associated lipids
Coronary Disease D003327 70 associated lipids
Intestinal Obstruction D007415 6 associated lipids
Pancreatitis D010195 10 associated lipids
Liver Cirrhosis, Experimental D008106 36 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Rhinitis D012220 10 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Asphyxia Neonatorum D001238 4 associated lipids
Melanoma D008545 69 associated lipids
Asthma D001249 52 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Staphylococcal Infections D013203 15 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Metabolism, Inborn Errors D008661 46 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Thrombosis D013927 49 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Peritonitis D010538 38 associated lipids
Hemorrhage D006470 15 associated lipids
Proteinuria D011507 30 associated lipids
Spasm D013035 5 associated lipids
Lymphoma D008223 18 associated lipids
Alzheimer Disease D000544 76 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Arteriosclerosis D001161 86 associated lipids
Leukemia D007938 74 associated lipids
Neuroblastoma D009447 66 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Thalassemia D013789 8 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Cholestasis D002779 23 associated lipids
Fibrosis D005355 23 associated lipids
Anemia, Sickle Cell D000755 34 associated lipids
Multiple Sclerosis D009103 13 associated lipids
Glomerulonephritis D005921 35 associated lipids
Nervous System Diseases D009422 37 associated lipids
Psoriasis D011565 47 associated lipids
Brain Edema D001929 20 associated lipids
Leukopenia D007970 9 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Staphylococcal Skin Infections D013207 9 associated lipids
Burns, Inhalation D002059 4 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Fetal Weight D020567 12 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Stroke D020521 32 associated lipids
Hyperlipoproteinemia Type II D006938 22 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemia D007511 18 associated lipids
Colonic Diseases D003108 5 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Alabaster VA et al. UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo. 1991 Agents Actions Suppl. pmid:1793066
Heuer HO The effects of hetrazepine PAF antagonists in preclinical models of asthma. 1991 Agents Actions Suppl. pmid:1793067
Mazzoni L et al. Changes in airway sensitivity to histamine are not necessarily paralleled by changed sensitivity to acetylcholine. 1991 Agents Actions Suppl. pmid:1793069
Billah MM et al. Sch 37370: a new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine. 1991 Agents Actions Suppl. pmid:1793070
Saeed SA et al. Inhibitory effect of oral ketotifen on ex vivo platelet activating factor-induced platelet aggregation. 1991 Agents Actions Suppl. pmid:1793071
Mest HJ et al. Effect of BN 52256 and other mediator antagonists on ouabain-induced ventricular fibrillation in sensitized guinea-pigs and on ischemia-induced fibrillation in rats. 1992 Agents Actions Suppl. pmid:1632298
Koltai M and Braquet PG Involvement of PAF in atherogenesis. Brief review. 1992 Agents Actions Suppl. pmid:1632308
McMillan RM and Carter GW Design and development of drugs. 1991 Agents Actions Suppl. pmid:1664186
Kurosawa M Effect of platelet activating factor on histamine release from rat mast cells. 1987 Agents Actions Suppl. pmid:2445185
Page CP and Spina D The therapeutic relevance of PAF antagonists. 1989 Agents Actions Suppl. pmid:2683635
Rink TJ Stimulus-response coupling mechanisms in human platelets. 1986 Agents Actions Suppl. pmid:3028101
Baroggi N et al. Changes in cytosolic free calcium induced by platelet-activating factor in rabbit platelets: specific inhibition by BN 52021 and structurally related compounds. 1986 Agents Actions Suppl. pmid:3028108
Etienne A et al. Antithrombotic activity of BN 50341, a structurally new compound with anticalcic and PAF-antagonistic properties. 1986 Agents Actions Suppl. pmid:3468781
PAF, platelets and asthma. Proceedings of a meeting. September 7-9, 1986. 1987 Agents Actions Suppl. pmid:3478993
Subissi A and Criscuoli M Effects of LG 30435 on different platelet activating factor-induced responses. 1988 Agents Actions Suppl. pmid:3262990
Heuer H and Casals-Stenzel J Effect of the PAF-antagonist WEB 2086 on anaphylactic lung reaction: comparison of inhalative and intravenous challenge. 1988 Agents Actions Suppl. pmid:3262991
Anderson GP and Fennessy MR Lipoxygenase metabolites as mediators of platelet activating factor-induced increased airways responsiveness to histamine in the guinea-pig. 1988 Agents Actions Suppl. pmid:3140616
Schrör K and Felsch A Ramiprilat prevents PAF-induced myocellular and endothelial injury in a neutrophil-perfused heart preparation. 1992 Agents Actions Suppl. pmid:1334351
Stenzel H et al. Effect of the PAF-antagonist SRI 63-441 on the allergic reaction in awake dogs with natural asthma. 1987 Agents Actions Suppl. pmid:2823582
O'Flaherty JT and Wykle RL Metabolic origin and fate of platelet-activating factor. 1987 Agents Actions Suppl. pmid:2823583
Bertrand C et al. Selective implication of thromboxane A2 and PAF-acether in two guinea pig anaphylactic models. 1990 Agents Actions Suppl. pmid:2080755
Tsunoda H et al. Effects of a novel PAF antagonist, E6123, on PAF-induced biological responses. 1990 Agents Actions Suppl. pmid:2080757
Sakuma Y et al. Effects of a novel PAF antagonist, E6123, on passive anaphylaxis. 1990 Agents Actions Suppl. pmid:2080758
Bult H et al. Complement derived factors and prostacyclin formation by rabbit isolated peritoneum and cultured mesothelial cells. 1984 Agents Actions Suppl. pmid:6382974
König W et al. On the biological role of lipid chemotactic factors. 1983 Agents Actions Suppl. pmid:6404145
Parnham MJ et al. Regulation of the oxidative burst of macrophages by lipid mediators. 1984 Agents Actions Suppl. pmid:6433680
Vargaftig BB Phospholipids, particularly platelet-activating factor (PAF-acether), in experimental bronchoconstriction. 1983 Agents Actions Suppl. pmid:6575594
Page CP et al. PAF-acether: a putative mediator of asthma and inflammation. 1983 Agents Actions Suppl. pmid:6575595
Hartung HP et al. Stimulation of the oxidative burst in macrophages with platelet activating factor (PAF-acether). 1982 Agents Actions Suppl. pmid:6960648
Madi S et al. Allergen-induced bronchospasm in passively sensitized guinea pigs: influence of new substances in comparison to reference compounds. 1991 Agents Actions pmid:2058463
Braquet P and Esanu A New trends in PAF antagonist research: a new series of potent hetrapazine-derived PAF antagonists. 1991 Agents Actions pmid:2058466
Northover AM Modification by some antagonists of the shape changes of venous endothelial cells in response to inflammatory agents in vitro. 1990 Agents Actions pmid:2111079
McLeod J et al. Effect of 12-O-tetradecanoylphorbol-13-acetate (TPA) on substance P-induced histamine release from rat peritoneal mast cells. 1990 Agents Actions pmid:1695435
Desai S and Barton R Role of platelet activating factor in the pathogenesis of active and passive models of experimental allergic encephalomyelitis in the rat. 1990 Agents Actions pmid:2285021
Adolfs MJ et al. PAF-acether modifies human peritoneal macrophage cAMP levels in a biphasic fashion. 1989 Agents Actions pmid:2540635
Neumann M and Kownatzki E The effect of adherence on the generation of reactive oxygen species by human neutrophilic granulocytes. 1989 Agents Actions pmid:2540640
Trebien HA and Calixto JB Pharmacological evaluation of rat paw oedema induced by Bothrops jararaca venom. 1989 Agents Actions pmid:2660497
Bekemeier H and Sänze JU Vasodepression ex vivo after administration of inflammatory mediators in vivo in the rat. 1989 Agents Actions pmid:2476918
Jouquey S et al. Comparison of the effects of the ace inhibitors trandolapril and enalapril on phlogogen induced foot pad oedema in the rat. 1988 Agents Actions pmid:2459935
Sanchez Crespo M and Nieto ML Modulation of PAF biosynthesis in human polymorphonuclear leukocytes. The role of phorbol esters and protein kinases. 1989 Agents Actions pmid:2711927
Zijlstra FJ et al. The effects of PAF-acether and FMLP on eicosanoid production in guinea pig alveolar macrophages. 1989 Agents Actions pmid:2711928
Nijkamp FP et al. Role of platelet activating factor in the endotoxin induced tracheal hyperreactivity to histamine in the guinea pig. 1989 Agents Actions pmid:2711929
Oliver JL et al. Effect of PAF acether on oriented egg phosphatidylcholine multibilayers; interaction with cholesterol; comparison to lyso-PC and lyso-PAF. 1989 Agents Actions pmid:2711930
Howat DW et al. An investigation into the possible involvement of platelet activating factor in experimental allergic encephalomyelitis in rats. 1989 Agents Actions pmid:2801340
Appleby P and Bowen JG Cutaneous inflammatory disorders. 1990 Agents Actions pmid:2117335
Lundgren JD et al. Platelet activating factor and tracheobronchial respiratory glycoconjugate release in feline and human explants: involvement of the lipoxygenase pathway. 1990 Agents Actions pmid:2117336
Nieminen MM et al. Body temperature modulates the effect of platelet-activating factor (PAF) on airways responsiveness in the rabbit. 1991 Agents Actions pmid:1862740
Jenei B et al. Hypotensive action of IgG preparations containing aggregates is suppressed by PAF-receptor antagonist BN 52021 and by gadolinium chloride (an agent blocking Kupffer cell function). 1991 Agents Actions pmid:1862750
Kantar A et al. Effect of PAF on erythrocyte membrane heterogeneity: a fluorescence study. 1991 Agents Actions pmid:1862752
Swingle KF and Reiter MJ Inhibition of Paf-acether-induced edema of the rat's paw. 1986 Agents Actions pmid:2875631
Flower RJ Background and discovery of lipocortins. 1986 Agents Actions pmid:2938452
Montrucchio G et al. The pattern of cardiovascular alterations induced by infusion of platelet-activating factor in rabbit is modified by pretreatment with H1-H2 receptor antagonists but not by cyclooxygenase inhibition. 1987 Agents Actions pmid:3115072
Carlson RP et al. Pharmacologic modulation of PAF-induced mortality in mice. 1987 Agents Actions pmid:3120513
Anderson GP et al. Increased airways responsiveness to histamine induced by platelet activating factor in the guinea-pig: possible role of lipoxygenase metabolites. 1988 Agents Actions pmid:3136622
Cahill M et al. Effect of des arginine9-bradykinin and other bradykinin fragments on the synthesis of prostacyclin and the binding of bradykinin by vascular cells in culture. 1988 Agents Actions pmid:3051930
Cunha FQ et al. Failure of PAF-acether to induce in vivo neutrophil migration. 1988 Agents Actions pmid:3055873
Ramesha CS et al. Identification and quantitation of PAF from psoriatic scales. 1987 Agents Actions pmid:3687590
Touvay C et al. Inhibition of antigen-induced lung anaphylaxis in the guinea-pig by BN 52021 a new specific paf-acether receptor antagonist isolated from Ginkgo biloba. 1986 Agents Actions pmid:3754380
Taira M et al. Lack of involvement of leukotriene and platelet activating factor in passive cutaneous anaphylaxis in rats. 1988 Agents Actions pmid:3407549
Etienne A et al. In vivo inhibition of plasma protein leakage and Salmonella enteritidis-induced mortality in the rat by a specific paf-acether antagonist: BN 52021. 1986 Agents Actions pmid:3515870
Mastacchi R et al. Interaction of a new low molecular weight heparin (OP/LMWH) with human platelets. 1986 Agents Actions pmid:3518359
Kusner EJ et al. Pharmacologic analysis of 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine-induced increases in cutaneous vascular permeability in the rat. 1987 Agents Actions pmid:3577957
Pettipher ER et al. PAF-acether in chronic arthritis. 1987 Agents Actions pmid:3630862
Archer CB et al. Actions of disodium cromoglycate (DSCG) on human skin responses to histamine, codeine and Paf-acether. 1985 Agents Actions pmid:3923788
Parente L et al. The effect of glucocorticoids on lyso-PAF formation in vitro and in vivo. 1986 Agents Actions pmid:3962774
Tarayre JP et al. Inflammatory action of PAF-acether in the rat pleural cavity. 1986 Agents Actions pmid:3962789
Pirotzky E et al. Vascular permeability induced by Paf-acether (platelet-activating factor) in the isolated perfused rat kidney. 1985 Agents Actions pmid:4003192
Page CP et al. Platelet activating factor (Paf-acether) may account for late-onset reactions to allergen inhalation. 1985 Agents Actions pmid:4003195
Page CP et al. Suppression of Paf-acether responses: an anti-inflammatory effect of anti-asthma drugs. 1985 Agents Actions pmid:4003196
Spicer BA et al. An investigation of the involvement of platelet activating factor in the non-histamine immediate hypersensitivity reaction in the rat peritoneal cavity. 1985 Agents Actions pmid:4003197
Boughton-Smith NK et al. Actions of nitric oxide on the acute gastrointestinal damage induced by PAF in the rat. 1992 Agents Actions pmid:1279960
Wong CW et al. Comparative effects of tetrandrine and berbamine on subcutaneous air pouch inflammation induced by interleukin-1, tumour necrosis factor and platelet-activating factor. 1992 Agents Actions pmid:1414679
Northover AM In vitro effects of PAF on venous endothelial cell actin disposition. 1992 Agents Actions pmid:1509977
Okamoto H et al. Suppression of the Arthus reaction by Y-24180, a potent and specific antagonist of platelet-activating factor. 1992 Agents Actions pmid:1388318
Rachmilewitz D et al. Cytokines and platelet-activating factor in human inflamed colonic mucosa. 1992 Agents Actions pmid:1359744
Ogunbiyi PO and Eyre P Pharmacological studies of pulmonary anaphylaxis in vitro: a review. 1985 Agents Actions pmid:2420161
Lewis AJ et al. The effects of antiallergic and bronchodilator drugs on platelet-activating factor (PAF-acether) induced bronchospasm and platelet aggregation. 1984 Agents Actions pmid:6152379
Benveniste J Platelet-activating factor (PAF-acether): present status. 1981 Agents Actions pmid:6176101
Northover AM and Northover BJ Lectin-induced increase in microvascular permeability to colloidal carbon in vitro may involve protein kinase C activation. 1994 Agents Actions pmid:7942320
Tubaro E et al. In vitro and in vivo impact of a new glycosphingolipid on neutrophils. 1994 Agents Actions pmid:7879694
Canale P et al. TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock. 1994 Agents Actions pmid:7879698
Kantar A et al. Effect of PAF on human lymphocyte membranes: a fluorescence study. 1993 Agents Actions pmid:8317302
Boonen GJ et al. Activation of neutrophil migration by dioctanoyl-sn-glycerol and fMet-Leu-Phe is controlled by different pathways. 1993 Agents Actions pmid:8317308
Murphy G Report of the 14th meeting of the British Inflammation Research Association. Topic: cellular and molecular aspects of inflammatory bowel disease. 1993 Agents Actions pmid:8480529
Sakamoto T et al. Effect of beta 2-adrenoceptor agonists against platelet-activating factor-induced airway microvascular leakage and bronchoconstriction in the guinea pig. 1993 Agents Actions pmid:7908496
Perret BA et al. Binding of bovine factor VIII-coated colloidal gold particles to receptors on platelet membranes. 1981 Agents Actions pmid:6803540
Denburg JA et al. Platelet activating factor: regulation by mast cells and aspirin. 1984 Agents Actions pmid:6711391
Lecrubier C et al. Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. 1983 Agents Actions pmid:6858789
Jouvin-Marche E et al. Platelet-activating factor (PAF-acether), an activator of neutrophil functions. 1982 Agents Actions pmid:6299078
Caillard CG et al. Hypotensive activity of PAF-acether in rats. 1982 Agents Actions pmid:6299079
Vargaftig BB Platelet-activating factor (PAF-acether) 1982 Agents Actions pmid:7164939
Bette P and Bienvenue A Exchange of a spin-labeled analog of PAF-acether between micelles, serum albumin and model membranes. 1982 Agents Actions pmid:7164940
Lartigue-Mattei C et al. Pharmacokinetic study of PAF-acether. Preliminary results after the intravenous administration of a 3H-labelled product to the rabbit. 1982 Agents Actions pmid:7164941
Morgat JL et al. Radio-labelling of 1-O-alkyl, 2-O-acetyl, sn-glycero-3-phosphorylcholine, 1-O-(9,10-di3H)-octadecyl PAF-acether. 1982 Agents Actions pmid:7164942
Vargaftig BB et al. Platelet-tissue interaction: role of platelet-activating factor (PAF-acether). 1980 Agents Actions pmid:7270336
Heller R et al. S35b, a new phenylsulfonylfuroxan compound, inhibits thrombin-induced synthesis of platelet-activating factor and prostacyclin in human endothelial cells. 1993 Agents Actions pmid:7517616
Lartigue-Mattei C et al. Pharmacokinetic study of 3H-labelled PAF-acether II. Comparison with 3H-labelled lyso-PAF-acether after intravenous administration in the rabbit and protein binding. 1984 Agents Actions pmid:6532184
Czarnetzki BM and Benveniste J Effect of synthetic PAF-acether on human neutrophil function. 1981 Agents Actions pmid:7041568
Camussi G et al. Neutropenia induced by platelet-activating factor (PAF-acether) released from neutrophils: the inhibitory effect of prostacyclin (PGI2). 1981 Agents Actions pmid:7041569
de Bernardis E et al. Protective effects of papaverine salicylate in mouse ear dermatitis and PAF-induced rat paw oedema. 1994 Agents Actions pmid:7847181